This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States)

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00620867
First received: February 12, 2008
Last updated: November 5, 2008
Last verified: November 2008
February 12, 2008
November 5, 2008
October 2002
March 2003   (Final data collection date for primary outcome measure)
Change from baseline in patient's assessment of arthritis pain according to visual analogue scale (VAS) [ Time Frame: Week 6 ]
Same as current
Complete list of historical versions of study NCT00620867 on ClinicalTrials.gov Archive Site
  • Vital signs [ Time Frame: Weeks 2 and 6 ]
  • Physical examination [ Time Frame: Week 6 ]
  • Laboratory test results [ Time Frame: Week 6 ]
  • Adverse events [ Time Frame: Weeks 2 and 6 ]
  • Change from baseline in patient's and physician's global assessment of pain [ Time Frame: Weeks 2 and 6 ]
  • Pain Satisfaction Scale [ Time Frame: Days 1-7 ]
  • Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index [ Time Frame: Week 6 ]
  • Patient Health Questionnaire (PHQ-9) [ Time Frame: Week 6 ]
  • Change from baseline in patient's assessment of arthritis pain according to VAS [ Time Frame: Week 2 ]
  • Vital signs [ Time Frame: Weeks 2 and 6 ]
  • Physical examination [ Time Frame: Week 6 ]
  • Laboratory test results [ Time Frame: Week 6 ]
  • Adverse events [ Time Frame: Weeks 2 and 6 ]
  • Change from baseline in patient's and physician's global assessment of pain [ Time Frame: Weeks 2 and 6 ]
  • Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index [ Time Frame: Week 6 ]
  • Pain Satisfaction Scale [ Time Frame: Days 1-7 ]
  • Patient Health Questionnaire (PHQ-9) [ Time Frame: Week 6 ]
  • Change from baseline in patient's assessment of arthritis pain according to VAS [ Time Frame: Week 2 ]
Not Provided
Not Provided
 
Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States)
A Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Three Times Daily Ibuprofen vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee
To compare the efficacy and safety of celecoxib versus ibuprofen in subjects with osteoarthritis (OA) of the knee.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Osteoarthritis, Knee
  • Drug: Ibuprofen
    800 mg oral tablet three time daily with meals for 6 weeks
  • Drug: celecoxib
    200 mg oral capsule once daily with morning meal for 6 weeks
  • Other: placebo
    matched placebo orally for 6 weeks
  • Experimental: Ibuprofen
    Intervention: Drug: Ibuprofen
  • Experimental: Celecoxib
    Intervention: Drug: celecoxib
  • Placebo Comparator: placebo
    Intervention: Other: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
393
March 2003
March 2003   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Aged >= 40 years old
  • Diagnosed with OA of the knee according to the American College of Rheumatology and OA in flare state at baseline visit
  • Functional capacity class of I-III

Exclusion Criteria:

  • Inflammatory arthritis or gout or pseudo-gout with acute flare within the past 2 years (subjects with fibrositis or fibromyalgia will not be excluded)
  • Acute joint trauma at index joint within the past 3 months with active symptoms
  • Score of >=20 on PHQ-9 or score of >=1 on PHQ-9 item i
  • Use of mobility assisting device for <6 weeks or use of walker
Sexes Eligible for Study: All
40 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00620867
A3191063
No
Not Provided
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP